Sanofi paying big for FDA voucher; Retrophin snags $245m

It didn't take Retrophin long to find a buyer for the FDA priority review voucher it snapped up in March when it exercised its rights to purchase the newly approved Cholbam (cholic acid) from Asklepion Pharmaceuticals for $27m plus 661,278 shares of the former firm's common stock.

It didn't take Retrophin long to find a buyer for the FDA priority review voucher it snapped up in March when it exercised its rights to purchase the newly approved Cholbam (cholic acid) from Asklepion Pharmaceuticals for $27m plus 661,278 shares of the former firm's common stock.

And its return on investment is a whooper.

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category